Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Vikram Premkumar"'
Publikováno v:
eJHaem, Vol 1, Iss 1, Pp 267-271 (2020)
Abstract Daratumumab is approved for use in newly diagnosed and relapsed/refractory multiple myeloma (MM), however the patients most likely to benefit from its addition to standard anti‐myeloma therapy is unclear. This meta‐analysis included 2340
Externí odkaz:
https://doaj.org/article/4669c3f319124476bd146f278a50f930
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:736-743
Since the introduction of proteasome inhibitors, immunomodulators, and monoclonal antibodies, the longevity of a patient with multiple myeloma has greatly improved. Although prognosis is improving, multiple myeloma remains an incurable disease and mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63bc125109cd40ea602a56cc9a65ca00
https://doi.org/10.1016/j.clml.2020.06.023
https://doi.org/10.1016/j.clml.2020.06.023
AL Amyloidosis (AL) is a plasma cell disease marked by production and deposition of toxic free light chains in organs including the heart, kidney and nervous system. While treatment is generally borrowed from multiple myeloma (MM), patients typically
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64863710033320ae5142d40b9146b767
https://europepmc.org/articles/PMC6954683/
https://europepmc.org/articles/PMC6954683/
Publikováno v:
Blood. 134:3161-3161
Background: Monoclonal gammopathy of renal significance (MGRS) is a monoclonal B cell disorder, not meeting the definition of lymphoma or myeloma, that produces monoclonal proteins which deposit in the kidneys. Permanent renal damage can occur either
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4045dda4da9753605348d37bc8bb465
https://doi.org/10.1182/blood-2019-123496
https://doi.org/10.1182/blood-2019-123496
Autor:
Divaya Bhutani, Suzanne Lentzsch, Vikram Premkumar, Andrew S. Bomback, Jai Radhakrishnan, Shayan Shirazayan
Publikováno v:
Blood. 134:5565-5565
Background: MGRS is a group of heterogeneous disorders characterized by renal dysfunction related to monoclonal immunoglobulin deposition where the underlying plasma cell or B cell clone does not cause tumor complications or meets current hematologic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d103137def61e2dfbf3374734a953be1
https://doi.org/10.1182/blood-2019-128455
https://doi.org/10.1182/blood-2019-128455